These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 6694274)

  • 1. Postmarketing drug surveillance.
    Borden EK; Gardner JS; Westland MM; Gardner SD
    JAMA; 1984 Feb; 251(6):729-30. PubMed ID: 6694274
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of adverse reactions within a drug surveillance program.
    Borda IT; Slone D; Jick H
    JAMA; 1968 Aug; 205(9):645-7. PubMed ID: 5695107
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug safety and the CSM.
    Goldberg A
    J R Soc Med; 1987 Feb; 80(2):67-8. PubMed ID: 3560146
    [No Abstract]   [Full Text] [Related]  

  • 4. Side-effects of drugs. Monitoring adverse reactions.
    Heenan A
    Nurs Times; 1989 Sep 27-Oct 3; 85(39):25-9. PubMed ID: 2587304
    [No Abstract]   [Full Text] [Related]  

  • 5. Post-marketing surveillance.
    Lasagna L
    Triangle; 1980; 19(3-4):107-11. PubMed ID: 7013216
    [No Abstract]   [Full Text] [Related]  

  • 6. Monitoring of adverse reactions to drugs in the United Kingdom.
    Inman WH
    Proc R Soc Med; 1970 Dec; 63(12):1302-4. PubMed ID: 5490790
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 8. [Basic principles of clinical evaluation of medications].
    Cichutek K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):395-6. PubMed ID: 15830248
    [No Abstract]   [Full Text] [Related]  

  • 9. Methodology for international drug monitoring.
    Royal BW; Venulet J
    Methods Inf Med; 1972 Apr; 11(2):75-86. PubMed ID: 5026576
    [No Abstract]   [Full Text] [Related]  

  • 10. The importance of postmarketing drug surveillance.
    Smart AJ; Walters L
    S Afr Med J; 1992 Dec; 82(6):383-4. PubMed ID: 1465681
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.
    Issa AM
    Pharmacogenomics; 2003 Sep; 4(5):647-55. PubMed ID: 12943471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statisical logic in the monitoring of reactions to therapeutic drugs.
    Finney DJ
    Methods Inf Med; 1971 Oct; 10(4):237-45. PubMed ID: 5124593
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug control.
    JENKINS GL
    Mon Bull Indiana State Board Health; 1945 Dec; 48():283. PubMed ID: 21009312
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse reactions to drugs.
    Kimbel KH
    Lancet; 1977 Feb; 1(8006):308. PubMed ID: 64832
    [No Abstract]   [Full Text] [Related]  

  • 15. [Abuse-related adverse drug reactions and abuse deterrent formulations].
    Papaseit E; Pérez-Mañá C; Torrens M; Farré M
    Med Clin (Barc); 2013 Nov; 141(10):454-8. PubMed ID: 24144061
    [No Abstract]   [Full Text] [Related]  

  • 16. Monitored drug usage in a hospital environment.
    Macgregor AG
    N Z Med J; 1969 Jun; 69(445):356-9. PubMed ID: 5257555
    [No Abstract]   [Full Text] [Related]  

  • 17. Discussion on control of new drugs.
    Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721
    [No Abstract]   [Full Text] [Related]  

  • 18. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 19. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse Drug Reactions Advisory Committee Report for 1976.
    Med J Aust; 1977 Nov; 2(20):682-3. PubMed ID: 607116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.